Estrella Immunopharma, Inc. (ESLA) shareholders
Close on Nov 17, 2026Market cap $14.42MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ESLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,975,220 | – | $4.13M | −123,780 | 0.05% |
| Vanguard Capital Management LLC | 416,852 | – | $433.53K | +34,383 | 0.00% |
| Geode Capital Management, LLC | 141,321 | – | $146.97K | −16,164 | 0.00% |
| Vanguard Fiduciary Trust Co | 64,921 | – | $67.52K | – | 0.00% |
| BlackRock, Inc. | 52,033 | – | $54.11K | +12,143 | 0.00% |
| State Street Corp | 43,252 | – | $44.98K | – | 0.00% |
| Renaissance Technologies LLC | 39,100 | – | $40.66K | −23,695 | 0.00% |
| Northern Trust Corp | 34,861 | – | $36.26K | +15,237 | 0.00% |
| US Bancorp \de\ | 20,000 | – | $20.80K | +3,096 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,308 | – | $3.44K | −1,551 | 0.00% |
| UBS Group AG | 1,721 | – | $1.79K | −13,358 | 0.00% |
| Toronto Dominion Bank | 1,089 | – | $1.13K | – | 0.00% |
| Wolverine Asset Management LLC | 468 | – | $487 | – | 0.00% |
| Barclays PLC | 126 | – | $131 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | – | $2 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 5M | 2 / 4 | 5 / 3 | 0M | 0M |
| Q1 2026 | 16 | 5M | 8 / 3 | 2 / 6 | 5M | 0M |
| Q4 2025 | 15 | 1M | 6 / 8 | 1 / 2 | 0M | 0M |
| Q3 2025 | 13 | 1M | 3 / 1 | 6 / 1 | 0M | 0M |
| Q2 2025 | 11 | 1M | 1 / 5 | 2 / 1 | 0M | 0M |
| Q1 2025 | 11 | 1M | 1 / 4 | 3 / 1 | 0M | 0M |
| Q4 2024 | 11 | 0M | 2 / 3 | 2 / 1 | 0M | 0M |
| Q3 2024 | 10 | 0M | 4 / 3 | 1 / 0 | 0M | 0M |
| Q2 2024 | 7 | 0M | 3 / 1 | 0 / 2 | 0M | 0M |
| Q1 2024 | 6 | 0M | 0 / 3 | 0 / 1 | 0M | 0M |
| Q4 2023 | 7 | 0M | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
8 funds held ESLA in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ESLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 268,605 | – | $279.35K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 148,247 | – | $154.18K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 99,247 | – | $108.18K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 49,660 | – | $51.65K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 27,548 | – | $30.03K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 16,762 | – | $18.27K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 2,373 | – | $2.47K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,582 | – | $1.72K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Cynthia Pussinen | Chief Executive Officer, Director | – | Nov 4, 2026 |
| Cheng Liu | CEO, Director | 397,437 | Aug 26, 2026 |
| Jiandong Xu | Chief Financial Officer | 382,188 | Aug 25, 2026 |
| Dengyao Jia | Director | – | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cheng Liu CEO, Director | Aug 25, 2026 | Option exercise | +100,000 | $0.82 | $82.00K | 397,437 |
| Jiandong Xu Chief Financial Officer | Aug 18, 2026 | Option exercise | +100,000 | $0.82 | $82.00K | 365,488 |
| Jiandong Xu Chief Financial Officer | Oct 7, 2025 | Buy | +1,000 | $1.33 | $1.33K | 265,488 |
| Jiandong Xu Chief Financial Officer | Sep 22, 2025 | Buy | +1,000 | $1.16 | $1.16K | 16,700 |
| Jiandong Xu Chief Financial Officer | Sep 11, 2025 | Buy | +100 | $1.04 | $104 | 264,588 |
| Jeffrey A. Altman 10% owner | Sep 29, 2023 | Other | −255,000 | $10.86 | $2.77M | 0 |
| Jianwei Li Co-Chief Executive Officer, Director, 10% owner | Mar 4, 2022 | Buy | +141,970 | $314700.00 | $44.68B | 1,253,730 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Estrella Immunopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,597 shares on Sep 10, 2026 over the last 90 days.
See a number that looks wrong?